echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > A variety of parenteral nutrition therapy drugs have been approved one after another, and the market of 10 billion yuan will be in waves

    A variety of parenteral nutrition therapy drugs have been approved one after another, and the market of 10 billion yuan will be in waves

    • Last Update: 2022-05-19
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Recently, Hengrui Medicine issued an announcement saying that it received the "Drug Registration Certificate" approved and issued by the State Drug Administration, and approved the company's medium and long-chain fatty emulsion/amino acid (16)/glucose (16%) injection to be classified as 4 types of chemicals.
    Eligibility for listing is deemed to have passed the consistency evaluation of the quality and efficacy of generic drugs

    .
    Medium and long chain fat emulsion/amino acid (16)/glucose (16%) injection is a parenteral nutrition preparation used to supplement the energy and nutrients required by human physiological functions

    .
    This product provides energy, essential fatty acids, amino acids, electrolytes and fluids required for parenteral nutrition therapy in patients with mild to moderately severe catabolism when oral or enteral nutrition is unavailable, insufficient, or contraindicated

    .
    The injection was developed by Germany's Braun Medical Co.
    , Ltd.
    and has been approved for listing in many countries, including China

    .
    In addition to the original manufacturers and companies, the products of two other domestic companies, Sichuan Kelun and Liaoning Hisco, have been approved for marketing and passed the consistency evaluation of generic drugs

    .
    Coincidentally, Kelun Pharmaceutical also issued two consecutive announcements recently, stating that the company's medium and long chain fat emulsion/amino acid (16)/glucose (36%) injection and medium and long chain fat emulsion/amino acid (16)/glucose (30%) %) injection was approved on the same day as the imitation class 3, which is regarded as over-evaluation.
    Both products are the first domestically approved products

    .
    The data show that medium and long chain fat emulsion/amino acid (16)/glucose (36%) injection and medium and long chain fat emulsion/amino acid (16)/glucose (30%) injection are also parenteral nutrition developed by German Braun.
    The therapeutic drug was approved for marketing in Sweden in 1999, and has been approved for marketing in many European countries such as the United Kingdom, Germany, and France

    .
    It is understood that with the approval of the above two drugs, Kelun Pharmaceutical has approved as many as 14 new parenteral nutrition products

    .
    It is worth mentioning that while the number of products continues to grow, Kelun Pharmaceutical is also constantly adjusting the variety structure to respond to policy changes

    .
    In 2021, Kelun Pharmaceutical will launch several new varieties in the field of parenteral nutrition, and the sales volume will increase by 12.
    72% year-on-year.

    .
    According to reports, in the next step, Kelun Pharmaceutical will further strengthen market coverage, promote the rational use of parenteral nutrition products in county-level medical institutions, and strengthen the allocation of all-in-one products.
    overall sales

    .
    The industry believes that the recent approval of a number of parenteral nutrition therapy drugs is mainly due to the increasing attention of many pharmaceutical companies to this market in recent years

    .
    According to IQVIA data, the global parenteral nutrition market reached nearly 10 billion yuan in 2019

    .
    With the continuous expansion of the market in recent years and the continuous increase of overweight companies, the number of approved drugs has naturally started to grow

    .
    However, it should be noted that competition in this field is expected to gradually intensify as the number of drug approvals continues to increase

    .
    Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone

    .
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.